Drug Type Synthetic peptide vaccine, Therapeutic vaccine |
Synonyms S-488210/Montanide, S-488211/Montanide, S 588210 + [1] |
Target |
Mechanism IGF2BP3 agonists(insulin like growth factor 2 mRNA binding protein 3 agonists), LY6K agonists(lymphocyte antigen 6 family member K agonists), NUF2 agonists(NUF2 component of NDC80 kinetochore complex agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mesothelioma | Phase 2 | - | - | |
Mesothelioma | Phase 2 | - | - | |
Bladder Cancer | Phase 1 | GB | 30 Jul 2019 | |
Esophageal Carcinoma | Phase 1 | GB | 30 Jul 2019 | |
Lung Cancer | Phase 1 | GB | 30 Jul 2019 | |
Relapsed Solid Neoplasm | Phase 1 | GB | 30 Jul 2019 | |
Unresectable Pleural Malignant Mesothelioma | Phase 1 | US | 12 Jun 2016 |
NCT04316689 (SITC2022) Manual | Phase 1 | 7 | wfdnboqwxm(imsojncxvh) = mjnlimwcty bngfkaqwnf (qlmkodqits ) View more | Positive | 01 Nov 2022 |